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Background: Premature birth is associated with decreased nephron number and
an increased risk for chronic kidney disease (CKD). To inform the development of
guidelines for kidney follow up of children born prematurely, we undertook a study of
individuals born extremely preterm, with the aim of characterizing the prevalence and
predictors of microalbuminuria, elevated blood pressure, and/or abnormal kidney volume
in adolescence.
Methods: Study participants (n = 42) were born before 28 weeks of gestation and
were enrolled at birth in the Extremely Low Gestational Age Newborns (ELGAN) study.
When participants were 15 years old, we obtained 2 manual blood pressures, a spot
urine microalbumin measurement, and sonographic measurements of kidney length
and volume.
Results: Of the 42 participants, 60% were male, 52% were Caucasian (18% Hispanic),
and 43% were African-American. Their median age was 15 (IQR 15, 15.3) years. In
33.3% of the cohort, blood pressure was elevated (>120/80 mmHg). Microalbuminuria
(>30 mg/g) was present in 11.9% of the cohort, and kidney volume below the 10th
percentile of normative data was present in 14%. Twenty-one (50%) of the sample had at
least one kidney abnormality (microalbuminuria, elevated blood pressures, and/or kidney
hypoplasia); these individuals were more likely to have experienced neonatal hypotension
[55% vs. 17% among those with no kidney abnormality, p = 0.02].
Conclusions: Half of adolescents in this subset of ELGAN cohort have at least one
risk factor of kidney disease (reduced kidney volume, microalbuminuria, and/or elevated
blood pressures) at 15 years of age. This study suggests the importance of monitoring
kidney outcomes in children after extremely preterm birth, especially those with a history
of neonatal hypotension.
Keywords: chronic kidney disease, pediatric, proteinuria, hypertension, kidney volume reduction, kidney
ultrasound, preterm birth, extremely preterm birth
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INTRODUCTION
Pediatric chronic kidney disease (CKD) carries a mortality
rate 1000-fold higher compared to the age-matched non-CKD
population, yet the initial onset of CKD is asymptomatic,
delaying diagnosis in pediatric patients (1). Delay in early
recognition of CKD is associated with more rapid disease
progression and earlier mortality among patients with End Stage
Kidney Disease (ESKD) (2, 3).
Preterm birth, which accounts for 10% of all births in the
US, is associated with a near doubling of the risk of CKD (4–7).
Harer et al. demonstrated that nearly a quarter of very low birth
weight infants had evidence of kidney dysfunction during early
childhood and South et al. found that adolescents with a history
of prematurity had higher blood pressures and decreased kidney
function compared to adolescents born at term (8, 9). Incomplete
nephrogenesis and the resultant poor nephron endowment
lead to proteinuria, hypertension, nephrotoxic inflammation,
tissue remodeling, and renal tubulo-interstitial fibrosis (8–12).
However, not all persons born with a reduced number of
nephrons (e.g., solitary kidney) develop CKD suggesting that
additional risk factors during the critical period of postnatal
nephron maturation and growth could contribute to progressive
loss of kidney function (10, 13–15).
Despite the increased risk of CKD among individuals born
preterm, evidenced-based guidelines have not been established
for kidney follow up of preterm infants after discharge from
the neonatal intensive care unit (NICU). Such guidelines might
allow for earlier diagnosis and application of therapies which
slow progression to ESRD (16, 17).
To inform the development of guidelines for kidney follow
up of individuals born extremely preterm, we evaluated kidney
outcomes in a sample of 15-year-old adolescents born extremely
preterm (prior to the third trimester) (18). Our objectives were to
evaluate, at 15 years of age, the prevalence of markers of early
evidence of kidney disease (microalbuminuria, hypertension,
and reduced kidney volume) and the association between
perinatal predictors.
METHODS
This is a prospective cohort study approved by the Institutional
Review Board of the University of North Carolina at Chapel
Hill (UNC-CH).
ELGAN Study Participants
Study participants were a subset of individuals (n = 42) enrolled
in the Extremely Low Gestational Age Newborn (ELGAN) study.
The ELGAN study is a multicenter prospective observational
study of infants born before 28 weeks gestation between April
2002 and August 2004. Infants were enrolled at birth at 14
hospitals in 5 states. The details of the population, IRB approvals,
consent, and methods have been previously described (18).
For the current study, we consecutively enrolled 42 ELGAN
study participants around the time of their 15th birthday at a
single site (University of North Carolina-Chapel Hill). Study
visits were completed between September 1, 2017 and April 31,
2019. A total of 53 ELGAN study participants were evaluated at
10 years of age at the University of North Carolina-Chapel Hill
and were eligible for the current study; 42 (79%) were enrolled.
Eleven potential participants were not enrolled due to lack of
transportation to the study site and/or scheduling conflicts. No
participants met criteria for exclusion, which included active
pregnancy or fever.
Figure 1 depicts the time course for data collection from the
original ELGAN study and for the ancillary kidney study visit.
Birth Characteristics From the ELGAN
Study, 2002–2004
Selected characteristics of the newborn period were abstracted
from the ELGAN database originally collected during each
participant’s neonatal intensive care unit (NICU) hospital course
from 2002 to 2004. The neonatal characteristics evaluated
in the current study were selected based upon prior studies
indicating a relationship between these neonatal characteristics
and nephrotoxicity or neonatal acute kidney injury (AKI) and
CKD (15, 19, 20). The following were abstracted from the
ELGAN study database: (1) delivery resuscitation interventions,
(2) APGAR scores, (3) diagnosis of sepsis within the first 28
days of life, (4) number of mechanical ventilator days in the first
28 days of life, (5) receipt of indomethacin for patent ductus
arteriosus (PDA) at any time during their NICU course, (6) urine
output in the first 12 h of life was recorded (converted toml/kg/hr
for analysis), (7) having an elevation (defined below) of a systemic
inflammatory marker (CRP, IGF, EPO, VEGFR, IL-8, TNF-α, IL-
6, and IL-1β), lowest mean arterial pressure(MAP) in the first 28
days of life, (9) diagnosis of neonatal hypotension as defined by
a lowest MAP in lowest quartile for gestational age, (10) use of
vasopressors in the first 14 days of life, (11) prolonged patent
ductus arteriosus, (12) number of doses of methylxanthines in
the first 28 days of life, (13) growth velocity throughout NICU
hospital course (grams/kg/day), (14) length of NICU course, and
(15) gestational age at birth and at hospital discharge (18).
Details of measurements of inflammatory proteins are
previously published (21). An elevation of an inflammatory
protein was defined as a concentration in the top quartile
for gestational age and postnatal day, and participants with
one or more inflammatory protein elevations within the
first two postnatal weeks were classified as having neonatal
systemic inflammation.
Kidney Measurements Collected During
ELGAN 15 Year-Old Kidney Study Visit,
2017–2019
The primary outcome was the presence of the composite
kidney outcome as defined by one or more of the following:
microalbuminuria, hypertension, and or reduced kidney volume,
based on evidence that individuals with these biomarkers are
at an increased risk for progressive CKD (estimated GFR <90
ml/min/1.73 m2) during childhood (17, 22–24).
Urine albumin/creatinine was measured in a random 1mL
urine clean catch sample which was refrigerated at 0–4.5 degrees
Celsius and delivered to UNC-CHMcLendon lab to be processed
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FIGURE 1 | ELGAN study data collection timeline.
within 12 h of sample collection. Urine creatinine was measured
enzymatically using the VITROS creatinine microslide (Mfr. No.
6802584) which uses an IDMS traceable method with calibration
to the National Institute of Standards and Technology (NIST)
SRM R© 914 creatinine reference standard. Urine albumin was
measured turbidometrically using antibodies specific for human
albumin (Mfr. No. 6801740). Immunochemical reactions of the
antibody/antigen complexes increase solution turbidity which is
measured spectrophotometrically at 340 nm. Testing for both
urine creatinine and urine albumin were performed in the
UNC-CH McLendon Laboratory on the VITROS 5600 System.
Microalbuminuria was defined as >30 µg albumin/milligram
creatinine (25). Two manual blood pressures were measured
after 5min of rest on the right upper extremity using FDA
approved MDF Instruments aneroid sphygmomanometer with
appropriately sized cuffs. Two blood pressures were measured
5min apart while the study participants were seated with
feet flat on the floor and were averaged for the final blood
pressure measurement. Participants were classified as having
hypertension if the mean of two blood pressure measurements
were greater than the 95th percentile for age, sex, and height
percentile or >120/80 mmHg consistent with the 2017 American
Academy of Pediatrics Clinical Practice Guidelines for Screening
and Management of High Blood Pressure in Children and
Adolescents (26).
Kidney volume was measured by ultrasonography using the
Sequoia S512 System with a 4C1 transducer and physician
ultrasonographers certified by Emory University School of
Medicine, “Ultrasonography for Nephrologists” course (27). Each
participant underwent renal ultrasound measurement of renal
length, width, and anterior-posterior diameter of both right and
left kidneys. All kidney dimensions were the maximum values of
the kidney with the patient lying in a prone position.
Kidney volume was calculated according to the volume
formula of a rotational ellipsoid:
RV[mL]=(Length∗Width∗Depth(anterior-posterior
diameter)) ∗π6 (28, 29).
Body surface area (BSA) was calculated according to D. Du Bois
and E.D. Du Bois as:
BSA[m2]=(body weight[kg]0.425∗body height[cm]0.725)
∗0.007184 (30).
BSA related renal volume (BSARV) was calculated as:
BSARV (ml/m2) = RV(mL)/BSA(m2).
Total kidney volume per body surface area was calculated by
summation of right and left kidney volumes then individualized
to body surface area:
(TKV/BSA = ml/m2).
Decreased kidney volumes or kidney hypoplasia was defined
by participants having TKV/BSA below the 10th percentile
of normative TKV/BSA per previously published data which
suggests that individuals with TKV/BSA in this range have an
inherent risk for oligonephropathy (28, 29, 31–33).
Statistical Analysis
Descriptive statistics included frequencies with percentage of
categorical variables and mean with standard deviation (SD)
or median with interquartile rang (IQR) of measures of
central tendency for continuous variables. Participants were then
categorized as having or not having the composite renal outcome,
as defined above. To evaluate directions of associations and
potential impacts of nephrotoxic neonatal exposures in this small
sample we used chi-square and Fisher’s exact test of significance
for categorical exposures. For continuous exposures, we used
Mann–Whitney U-test (for independent variables with non-
normal distribution) or t-tests (for independent variables that
were normally distributed).
The comparisons were done between renal volume in the
ELGAN sample and previously published normative data on
renal volume (28, 29, 31). P-values were calculated by t-test for
normal distribution.
Univariate logistic regressionmodels were used to estimates of
the strength of association between neonatal exposures and the
composite renal outcome. Given the size of this sample, we did
not perform multivariable analyses. Statistical significance was
defined as a p-value of <0.05, but our main goal was to evaluate
direction and potential impacts for guiding future research,
including calculation of sample sizes needed. All analyses were
conducted with SAS (v.9.4, Cary, N.C.).
RESULTS
Study Participants
The median age of the cohort was 15.0 (IQR 15.0, 15.3) years,
59.5% were male, 52.38% were Caucasian (18.1% Hispanic),
and 42.9% were African-Americans. The mean body mass index
(BMI) percentile was at the 71st percentile for age and sex and
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52.4% participants were overweight (BMI greater than the 85th
percentile for age and sex) (34). Mean gestational age a birth was
25.7 (±1.1) weeks and mean birth weight was 770 (±173) grams
(Table 1).
Kidney Outcomes
The median systolic and diastolic blood pressures of the ELGAN
cohort were 115.8 (IQR: 10,9122) and 70 (IQR: 6,476) mmHg.
While the overall mean systolic and diastolic blood pressures
were within the normal range, 33.3% of the cohort had elevated
systolic and/or diastolic blood pressures (>120/80 mmHg). The
median systolic blood pressure for adolescents with the presence
of the composite kidney outcome was significantly elevated
[121 (IQR: 111,125.5) mmHg] compared to a mean systolic
blood pressure of 111 (IQR: 107,116) mmHg among adolescents
without the composite kidney outcome (p < 0.01). However, no
difference was found when comparing diastolic blood pressure
for those with and without the composite kidney outcome. Of the
adolescents with systolic and/or diastolic blood pressure>120/80
mmHg, themean systolic blood pressure was 124.68± 3.4mmHg
and 76.18± 9.6 mmHg.
Median spot urine albumin/creatinine ratio was 7.6 (IQR: 5.4,
14.9) mg/g. However, 11.9% of the cohort demonstrated evidence
of microalbuminuria (>30 mg/g). Among the nine participants
with only microalbuminuria, the mean urine albumin/creatinine
was 95.4± 72.8 mg/g.
When comparing this ELGAN study cohort to age and sex-
matched normative data (28, 29, 31), there were no clinically or
statistically significant differences in kidney length and volume
(Table 2). Mean right and left kidney length were 9.4 (±0.7) cm
and 9.7 (±0.9) cm, compared to normative kidney length data
(normative right kidney 9.2 ± 0.7 cm (p = 0.54), normative left
kidney 9.9 ± 0.6 cm) (p = 0.46), respectively. Mean total kidney
volume per body surface area (TKV/BSA) was 126.4 (±26.7)
ml/m2 compared to the pediatric normative mean TKV/BSA
(132 (±31.3) ml/m2) (p= 0.19).
Overall, 50% of the adolescent cohort (n = 21) had
one or more biomarkers of CKD as evidenced by elevated
blood pressures, microalbuminuria, and or reduced kidney
volume measurement by kidney ultrasound. None of the
participants had a prior knowledge of a history of kidney
disease, elevated blood pressures, proteinuria, or known
structural abnormalities of the kidney, and/or urinary tract.
Kidney volumes among the adolescents with and without the
presence of the composite kidney outcome (microalbuminuria,
hypertension, and or reduced kidney volumes) were not
statistically different [TKV/BSA 125.2 ± 32.7 vs. 127.6 ± 19.7
ml/m2 vs., respectively (p= 0.09)]. However, 14.3% of the cohort
demonstrated kidney volume less than the 10th percentile BSA
normalized kidney volume normative data, a marker previously
reported to be associated with oligonephropathy (Table 2) (32).
Of note, there were no statistical differences in the presence of
albuminuria, hypertension, and/or reduced kidney volume by
race, overweight status, or sex (Table 1). Of note, we did not find
differences in the presence of albuminuria, hypertension, and/or
reduced kidney volume by race, overweight status, or sex.
Neonatal Risk Factors
We compared birth and demographic characteristics in the
adolescents with and without the composite kidney outcome
of elevated blood pressure, microalbuminuria, and/or abnormal
kidney volume (Table 1). Adolescents with the composite
outcome, as compared to those without this outcome had similar
gestational ages at birth (26.0± 1.1 vs. 25.4± 1.1 weeks, p= 0.13)
and birth weights (741.4 ± 142.4 vs. 808.1 ± 205.3 grams, p =
0.22) (Table 1). However, the frequency of neonatal hypotension
(as defined by having a lowest MAP in the lowest quartile for
age) was significantly greater (55 vs. 17%, p = 0.02) in those
with the presence of the composite kidney outcome. We found
no other neonatal clinical differences between adolescents with
and without the composite kidney outcome.
In the univariate logistic regression analyses, there were
no neonatal characteristics that were statistically significantly
associated with the composite kidney outcome although neonatal
hypotension approached significance with a wide confidence
interval (OR 3.52, 95%CI 0.94, 13.17; p= 0.06).
DISCUSSION
The most important finding from this study is that in a
sample of adolescents born extremely preterm, 50% had one
or more abnormalities associated with CKD (microalbuminuria,
elevated blood pressures, and/or reduced kidney volumes).
This prevalence is higher than the sum of the prevalence’s of
microalbuminuria (<3%), hypertension (3–5%), and congenital
kidney anomalies (<1%) reported in the general pediatric
population (26, 35–37).
As compared to prior studies involving children born
preterm, our study demonstrates a higher prevalence of elevated
blood pressures and microalbuminuria. In a sample of 422
young adults born before 32 weeks of gestation, 10% had
elevated blood pressure and 2.7% had microalbuminuria, as
compared to 33.3% with elevated blood pressures and 11.9%
with microalbuminuria in the sample described here (38, 39).
Likely explanations are that the mean gestational age and
birth weight were lower in our sample as compared to those
studied previously, and the relatively high frequency of African-
American (42.9%) and overweight (53.8%) children in our cohort
(34, 40–46). Both overweight status and African-American race
are independent risk factors for CKD related to hyperfiltration,
obesity related focal segmental glomerulosclerosis, and the
genetic predisposition to develop CKD (6, 44, 47).
In contrast to prior studies, we found no difference between
total kidney volume per BSA(TKV/BSA) in children born
extremely premature, as compared to normative pediatric kidney
ultrasound data (22, 48–51). Nearly 60% of human nephrons
are formed during the second and third trimesters of gestation,
and renal autopsy studies have shown that the total number
of nephrons correlates with gestational age at birth (10–12).
Infants born prematurely, and thus during a period of relatively
rapid nephrogenesis have reduced nephron endowment, reduced
kidney volume, and increased risk for CKD long-term (5, 11,
52). On the other hand, some infants born prematurely achieve
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TABLE 1 | ELGAN study birth characteristics collected in 2002–2004 and ancillary kidney study visit data collected in 2017–2019 by composite kidney outcome
(microalbuminuria, elevated blood pressure, and/or abnormal kidney mass by ultrasound* ).
Characteristics Total
(n = 42)





Birth characteristics collected 2002–2004
Gestational age at birth (weeks), mean(SD) 25.7 ± 1.1 25.5 ± 1.0 26.0 ± 1.1 0.13
Birth weight (grams), mean(SD) 770.0 ± 173.1 807.2 ± 190.3 732.8 ± 149.3 0.22
Delivery resuscitation interventions, n (%) 0.94
Missing 1 (2.4%) 0 (0.0%) 1 (4.8%)
Positive pressure ventilation 5 (11.9%) 3 (14.3%) 2 (9.5%)
Intubation 33 (78.6%) 16 (76.2%) 17 (81.0%)
Compressions 1 (2.4%) 1 (4.8%) 0 (0.00%)
Epinephrine 2 (4.8%) 1 (4.8%) 1 (4.8%)
APGAR 1min, md(IQR) 4.5 (2.0, 7.0) 5.00 (2.0, 6.0) 4.0 (3.0, 7.0) 0.45
APGAR 5min, md(IQR) 7.0 (5.0, 8.0) 7.0 (5.0, 8.0) 7.00 (6.00, 8.00) 0.56
Neonatal indomethacin exposure, n (%) 19 (45.2%) 11 (52.4%) 8 (38.1%) 0.35
Neonatal sepsis in 1st month, n (%) 0.70
Missing 1 (2.4%) 1 (4.8%) 0 (0.0%)
No 31 (73.8%) 16 (76.2%) 15 (71.4%)
Yes 10 (23.8%) 4 (19.1%) 6 (28.57%)
Mechanical ventilator days, md (IQR) 19.0 (5.0, 28.0) 26.5 (8.0, 28.0) 14.0 (4.0, 28.0) 0.31
Urine output (ml/kg/hr), mean(SD) δ 1.6 ±1.1 1.7 ± 1.3 1.4 ± 0.9 0.11
Any inflammatory proteins >75th percentile, n (%)U 26 (61.9%) 12 (57.1%) 14 (66.7%) 0.75
Duration of NICU course (weeks), mean(SD) 12.7 ± 6.9 14.2 ± 8.3 11.1 ± 4.8 0.06
Lowest MAP(mmHg), med (IQR) 23.0 (19.0, 27.0) 23.0 (21.0, 29.0) 20.0 (17.0, 25.0) 0.10
Hypotension, n (%) 16 (38.1%) 5 (23.8%) 11 (52.4%) 0.0236
Use of vasopressors in first 14 days of life, n (%) 21 (50%) 8 (38.1%) 13 (61.9%) 0.35
Any patent ductus arteriosus, n (%) 28 (66.7%) 12 (57.1%) 16 (76.2%) 0.21
# of Doses of methylxanthine in first 28 days, md(IQR) 10.0 (0.0, 24.0) 5 (0.0, 22.0) 12.0 (2.0, 25.0) 0.11
Growth velocity (g/kg/day), mean(SD)** 24.6 ± 8.6 24.7 ± 8.7 24.6 ± 8.7 0.64
Gestational age at discharge, mean(SD) 38.4 ± 6.5 39.7 ± 7.9 37.1 ± 4.3 0.09
Ancillary 15-year old renal study visit characteristics collected 2017–2019
Age (years), med (IQR) 15.0 (15.0, 15.3) 15.0 (15.0, 15.1) 15.1 (15.0, 15.4) 0.47
Males, n (%) 25 (59.5%) 10 (47.6%) 15 (71.4%) 0.35
Race, n (%) 0.67
Caucasian 22 (52.4%) 11 (52.4%) 11 (52.4%)
African-American 18 (42.9%) 9 (42.9%) 9 (42.9%)
Other 2 (4.8%) 1 (4.8%) 1 (4.8%)
BMI >85th percentile, n (%) 22 (52.4%) 10 (47.6%) 12 (57.1%) 0.53
BMI percentile, mean(SD) 70.7 ± 30.2 70.2 ± 29.8 71.1 ± 31.0 0.92
Elevated blood pressure (>120/80 mmHg), n (%) 14 (33.3%) 0 (0.0%) 14 (58.3%) –
Systolic blood pressure (mmHg), med (IQR) 115.8 (109.0, 121.5) 111.0 (107.0, 116.0) 121.0 (111.0, 125.5) 0.0021
Diastolic blood pressure (mmHg), med (IQR) 70.0 (64.0, 76.0) 69.5 (64.0, 73.0) 71.0 (66.0, 81.0) 0.25
Renal hypoplasia*, n (%) 6 (14.3%) 0 (0.0%) 6 (28.6%) –
Right renal length (cm), mean(SD) 9.4 ± 0.7 9.4 ± 0.9 9.3 ± 0.6 0.12
Left renal length (cm), mean(SD) 9.7 ± 0.9 9.8 ± 1.0 9.6 ± 0.8 0.09
Microalbuminuria (>30µg/g), n (%) 5 (11.9%) 0 (0.0%) 5 (23.8%) –
Urine albumin/creatinine (µg/g), md(IQR) 7.6 (5.4, 14.9) 6.7 (4.6, 11.8) 12.5 (5.9, 30.7) 0.0253
*Abnormal renal mass defined by body surface area related renal volume below mean and standard deviation.
δUrine output in the first 12 h of life.
U Inflammatory proteins measured at birth include CRP, IGF, EPO, VEGFR, IL-8, TNF-α, IL-6, and IL-1β.
**Growth Velocity = [(Discharge weight-birthweight)/birthweight]/Length of Stay (18).
#lowest MAP in lowest quartile for gestational age.
***P-values were calculated by Chi-square and Fisher’s exact test of significance for categorical independent variables, Mannz–Whitney U-test for non-parametric interval independent
variables, t-test of significance used for interval independent variables.
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TABLE 2 | Mean (SD) renal ultrasound measurements from adolescent participants of the UNC-CH ELGAN study who participated in a kidney study visit (2017–2019),












n = 42 n**
Right kidney length (cm) 9.4 ± 0.9 9.3 ± 0.6 9.4 ± 0.7 9.2 ± 0.7 0.54
Right body surface area related kidney volume (ml/m2 ) 61.6 ± 10.0 62.1 ± 20.3 61.8 ± 15.8 65.4 ± 15.2 0.14
Left kidney length (cm) 9.8 ± 1.0 9.6 ± 0.8 9.7 ± 0.9 9.9 ± 0.6 0.46
Left body surface area related kidney volume (ml/m2 ) 66.0 ± 14.0 63.1 ± 15.1 64.6 ± 14.5 66.3 ± 15.9 0.49
Total kidney volume per body surface area (ml/m2 ) 127.6 ± 19.7 125.2 ± 32.7 126.4 ± 26.7 132 ± 31.3 0.26
*Normative data references (28–30).
**n, The normative data sample size for kidney lengths is 11 and the normative data sample size for kidney volumes is 624.
***P-values were calculated, by t-test for comparison between ELGAN Cohort and Normative data.
normal TKV/BSA post-term (33). Our finding that children
with TKV/BSA below the 10th percentile of normative data
had a greater decrease in kidney size in the left kidney length
compared to right kidney length is consistent with findings from
a study of kidney length and volumes among young adults born
preterm (22).
We found that none of the hypothesized neonatal risk factors
were associated with the presence of one or more abnormal
kidney outcome (microalbuminuria, elevated blood pressures,
and/or reduced kidney volume) during adolescence. Yamamura-
Miyazaki et al. found that a lower 5-min Apgar was associated
with decreased cystatin C-estimated glomerular filtration rate in
school aged children after preterm birth (46). This could not
be assessed here as glomerular filtration rate was not assessed
in the ELGAN sample. A history of neonatal hypotension
was more prevalent among adolescents in this cohort with
the composite kidney outcome, but an association between
neonatal hypotension and an abnormal kidney outcome was not
significant in the univariate analyses. Further study of these risk
factors is needed in large samples, as hypotension after preterm
birth might compromise renal perfusion during a critical period
of post-natal nephron development and maturation. Studies with
larger sample sizes could identify risk factors for adverse kidney
outcomes so that infants with these risk factors can be more
frequently monitored after discharge from the neonatal intensive
care unit.
Strengths of our study include selection of a cohort based on
gestational age, not birth weight, which minimized confounding
due to factors related to growth restriction (53). Another strength
is the use of non-invasive markers of kidney disease that have
been shown to be predictive of long term CKD and more
rapid progression of kidney disease (23, 24). With advancements
in ultrasonography in outpatient office settings, the approach
we used to evaluate kidney outcomes could serve as a non-
invasive screening approach for use by primary care physicians
and nephrologists.
The study has limitations including the small sample size,
which reduces the generalizability of the study and the statistical
power to detect associations with early life exposures. Serum
creatinine and cystatin-c are more widely accepted and valid
markers for evaluation of kidney dysfunction, but we did
not collect blood samples from study participants. Spot urine
microalbumin to creatinine samples were used to support rapid
screening of patients in this study, however, this could potentially
overestimate the frequency of microalbuminuria due to potential
contribution of orthostatic proteinuria and other causes of
albuminuria. Elevated blood pressures were diagnosed bymanual
blood pressure measurements though 24-h ambulatory blood
pressure monitoring (24 hr ABPM) studies are the preferred
method for diagnosis of systemic hypertension. In future studies,
first morning urine samples and 24 hr ABPM studies should be
obtained to reduce potential misclassifications.
In conclusion, our study suggests that children born
extremely prematurely are at increased risk for developing
elevated blood pressures, microalbuminuria, or decreased kidney
volumes during adolescence. We hope this preliminary study
will lead to future studies with larger samples sizes to
determine whether our findings can be replicated in other
samples of individuals born extremely preterm and to better
define neonatal exposures which might compound the risk
for kidney disease during childhood. If the larger studies that
we intend to pursue replicate our preliminary study findings
of increased risk for CKD among children born extremely
preterm, this would provide greater evidence to support early
and perhaps annual screening for these children such that early
interventions, which delay the progression of CKD, can be
effectively employed.
Finally, although we and others continue to document
that extremely low gestational age newborns are at risk
for CKD, to date there are no evidence-based consensus
guidelines for follow up of kidney health after extremely preterm
birth. Larger, long-term multi-site studies of individuals born
extremely preterm will help determine the best evidence-based
approach to kidney follow up after extremely preterm birth.
Currently, the AAP recommends after discharge from neonatal
intensive care, premature infants should have monitoring of
blood pressure and growth with every well-child care visit
(26). We believe that this recommendation should also be
followed for each visit to high risk infant follow-up clinics.
We believe that additional monitoring of serum creatinine,
electrolytes, kidney ultrasound, and urine microalbumin should
be performed in premature infants at well-child care visits,
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especially if they have a history of acute kidney injury, are
extremely premature, small for gestational age, intrauterine
growth restricted, and/or if they have other risk factors for CKD
(e.g., congenital kidney abnormalities, diabetes mellitus), chronic
medical comorbidities(e.g., chronic lung disease, congenital heart
disease), overweight/obesity (BMI >85th percentile), and/or BP
>95th percentile. We emphasize that these approaches are not
consensus guidelines but rather, are based on opinions of authors.
There is a great need to further study which premature infants,
which tests, and what recommendations should be provided to
those at risk for CKD and those with CKD for individuals born
extremely preterm.
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